To compare the 30-day safety and efficacy of the GORE Flow Reversal System when used with approved carotid stents to an Objective Performance Criterion derived from distal embolic protection studies.
The GORE Flow Reversal System, manufactured by W. L. Gore \& Associates, Inc., was developed as a proximal occlusion device to reverse the flow of blood in the carotid artery. It is designed to achieve embolic protection prior to crossing the lesion in the majority of cases in order to minimize the possibility of an adverse event occurrence. The objective of this study is to assess the safety and effectiveness of the GORE Flow Reversal System when used to provide embolic protection during Carotid Artery Stent (CAS) procedures. Subjects diagnosed with carotid stenosis requiring revascularization and are at high risk for adverse events from CEA are eligible to participate.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
245
Carotid artery angioplasty and stenting with embolic protection
Millard Fillmore Gates/Univ. of Buffalo
Buffalo, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Composite Major Adverse Event (MAE) Rate
Number of participants with one or more Major Adverse Event (death, stroke, myocardial infarction, and/or transient ischemic attack (TIA)) through the 30-day follow-up (non-hierarchical; MAE adjudicated by independent Clinical Events Committee)
Time frame: Treatment through 30-day visit window
Flow Reversal System Technical Success
Number of participants with Technical Success using the GORE Flow Reversal System (system deployed and utilized during stenting procedure)
Time frame: Procedure
Flow Reversal System Success
Number of participants where the GORE Flow Reversal System was delivered, placed, reverse flow was established, and the balloon sheath and wire retrieved as outlined in the Instructions for Use without causing any adverse events during the procedure.
Time frame: Procedure
Stent Success
Number of participants where the FDA-approved stent was successfully delivered, deployed,and delivery system removed with an attainment of \< 50% residual stenosis following stent placement, as assessed by the angiographic core laboratory.
Time frame: Procedure
Clinical Success
Number of participants with Flow Reversal System and Stent Success in the absence of death, emergency endarterectomy, repeat percutaneous transluminal angioplasty (PTA)/thrombolysis of the target vessel, stroke, or myocardial infarction (MI), as determined by the Clinical Events Committee (CEC).
Time frame: 24-48 Hours Post-Procedure
Patency at 30 Days
Number of participants with less than 50% restenosis as determined by carotid duplex ultrasound core laboratory at 30 days post-procedure.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Treatment through 30-day visit window